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a b s t r a c t 
Resveratrol is a naturally occurring polyphenolic antioxidant that has received massive attention for its 
potential health beneﬁts, including anticarcinogenesis, anti-aging and antimicrobial properties. The com- 
pound is well tolerated by humans and in recent years has been widely used as a nutraceutical. Its com- 
mon use makes it interesting to investigate with respect to antimicrobial properties both as a single agent 
and in combination with conventional antibiotics. Resveratrol displays antimicrobial activity against a sur- 
prisingly wide range of bacterial, viral and fungal species. At subinhibitory concentrations, resveratrol can 
alter bacterial expression of virulence traits leading to reduced toxin production, inhibition of bioﬁlm 
formation, reduced motility and interference with quorum sensing. In combination with conventional an- 
tibiotics, resveratrol enhances the activity of aminoglycosides against Staphylococcus aureus , whereas it 
antagonises the lethal activity of ﬂuoroquinolones against S. aureus and Escherichia coli . Whilst the an- 
timicrobial properties of the compound have been extensively studied in vitro, little is known about its 
eﬃcacy in vivo. Nonetheless, following topical application resveratrol has alleviated acne lesions caused 
by the bacterium Propionibacterium acnes . There are currently no in vivo studies addressing its effect in 
combination with antibiotics, but recent research suggests that there may be a potential for enhancing 
the antimicrobial eﬃcacy of certain existing antibiotic classes in combination with resveratrol. Given the 
diﬃculties associated with introducing new antimicrobial agents to the market, nutraceuticals such as 
resveratrol may prove to be interesting candidates when searching for solutions for the growing problem 
of antimicrobial resistance. 
© 2019 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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n  1. Introduction: beneﬁcial health effects of resveratrol 
In recent years, resveratrol has attracted immense attention due
to its potential health beneﬁts [1] . One example is known as the
‘French paradox’, where consumption of red wine, having a high
content of resveratrol, has been linked to low mortality caused by
cardiovascular diseases in the French population despite their high
intake of saturated fat [2,3] . 
Since then, resveratrol has been extensively studied for a
variety of different health-beneﬁcial effects, including, but not lim-
ited to, anti-inﬂammation, anti-carcinogenesis, anti-obesity, anti-
diabetes type 2, anti-aging, cardiovascular protection and neuro-
protection, which is reviewed elsewhere and therefore is not the
focus of this review [4–7] . In addition to the extensive inves-
tigations on a multitude of diseases, resveratrol has also been
examined for its antimicrobial properties against bacteria, fungi∗ Corresponding author. 
E-mail address: hi@sund.ku.dk (H. Ingmer). 
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0924-8579/© 2019 The Author(s). Published by Elsevier B.V. This is an open access article
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) nd viruses. This review concerns the antimicrobial properties of
esveratrol, with special emphasis on its antibacterial properties. 
. Natural occurrence and structure of resveratrol 
Resveratrol (3,5,4’-trihydroxystilbene) is a naturally occurring
olyphenolic antioxidant belonging to the stilbene family. The
tilbene family consists of a C6–C2–C6 carbon skeleton (1,2-
iphenylethylene), where resveratrol is a hydroxylated derivative
 Fig. 1 ) [8] . Resveratrol is present in numerous plants such as
eanuts ( Arachis hypogea ), blueberries and cranberries ( Vaccinium
pp.), Japanese knotweed ( Polygonum cuspidatum ) a traditional
sian herbal medicine, and most importantly as a natural source
or human consumption in grapevines ( Vitis vinifera ) [9] . Being a
atural phytoalexin, resveratrol is synthesised de novo by plants in
esponse to damage by fungal attack [10–12] and ultraviolet (UV)
rradiation [10] . In a bunch of grapes, resveratrol synthesis is most
redominant in the non-infected grapes that surround grapes in-
ected with a fungus to limit the spread of the fungus to healthy
rapes, as demonstrated with the fungus Botrytis cinerea , the causalunder the CC BY-NC-ND license. 
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Fig. 1. Structure of resveratrol. 
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f  rganism of grey mould [13] . Resveratrol exists both in a cis and
rans isomer [4] , with the trans isomer being the most abundant
orm in red wine [14] and the most studied due to its greater avail-
bility and higher stability [15] . Red wine generally has a greater
oncentration of resveratrol than white wine [16] . The average red
ine contains 1.9 mg/L trans -resveratrol but it may reach concen-
rations up to 14.3 mg/L [14] . 
. Antibacterial targets for resveratrol 
Resveratrol is a promiscuous molecule that interacts with more
han 20 proteins in eukaryotic organisms [17] . As an example, crys-
allisation complexes have determined a binding site for resvera-
rol to bovine ATP synthase in the F 1 -domain in a pocket between
 β-subunit and the γ -subunit [18] . Conservation of the ATP syn-
hase residues suggests a similar binding pocket for resveratrol in
scherichia coli [19] . Resveratrol binds reversibly to ATP synthase,
artially inhibiting both ATP hydrolysis and ATP synthesis func-
ions of the ATP synthase in the facultative aerobe E. coli [19] . ATP
ydrolysis is also inhibited in Mycobacterium smegmatis [20] , and
he metabolic activity of Arcobacter spp. is reduced by resveratrol
21] . Supplementation of resveratrol to E. coli cells prevents growth
n the non-fermentable carbon source succinate and limits growth
n fermentable glucose, suggesting that resveratrol inhibits oxida-
ive phosphorylation [19] . As E. coli mutants lacking ATP synthase
re able to grow in the presence of fermentable carbon sources
uch as glucose, pyruvate or lactate, ATP synthase cannot be the
nly target leading to growth inhibition in E. coli [22] . Second,
esveratrol induces DNA fragmentation and concomitant upregu-
ation of the SOS stress-response regulon in E. coli , however in-
ibition of growth is not directly related to DNA fragmentation
nd SOS stress-response upregulation [23] . Resveratrol-treated E.
oli cells are elongated, hence the cell division apparatus is also
ffected by resveratrol and this occurs via suppression of ftsZ ex-
ression [23] . FtsZ is a key protein in septum formation during cell
ivision and thus resveratrol is suggested to inhibit FtsZ-mediated
eptum formation and cell division [23] . Finally, resveratrol treat-
ent has been correlated with membrane damage of cells ow-
ng to increased potassium leakage and increased propidium iodide
ptake [24] . In contrast, resveratrol-induced membrane damage is
ot detected for Staphylococcus aureus [25] . 
The pleiotropic effects of resveratrol suggest that multiple tar-
ets may exist in bacterial species, however the mechanism for
acterial growth inhibition remains incompletely understood. . Antifungal and antibacterial activities of resveratrol 
Resveratrol has been extensively studied for its ability to inhibit
he growth of bacteria, fungi and viruses. Antiviral activities are
eviewed elsewhere and have therefore been omitted from this re-
iew [26,27] . 
.1. Antifungal activity 
Generally, resveratrol displays better antifungal than antibac-
erial activity, as demonstrated by the minimum inhibitory con-
entrations (MICs) highlighted in Table 1 . For the fungal dermato-
hytes Trichophyton mentagrophytes, Trichophyton tonsurans, Tri- 
hophyton rubrum, Epidermophyton ﬂoccosum and Microsporum gyp-
eum , the inhibitory activity of resveratrol is approximately 25–
0 μg/mL [28] . For the fungal species Candida albicans, Saccha-
omyces cerevisiae and Trichosporon beigelii , the inhibitory activity
s 10–20 μg/mL [29] , however other studies have not detected an-
ifungal activity against C. albicans [30–32] . Resveratrol displays in-
ibitory activity against the plant pathogen B. cinerea , the causal
rganism of grey mould, where reduced germination of B. cinerea
onidia and mycelial growth is observed at concentrations of 60–
40 μg/mL [11] . 
.2. Antibacterial activity 
For a limited number of bacterial species, resveratrol in-
ibits growth at concentrations < 100 μg/mL, including Bacillus
ereus (MIC = 50 μg/mL) [33] , M. smegmatis (MIC = 64 μg/mL) [34] ,
elicobacter pylori (MIC = 25–50 μg/mL) [35–37] , Vibrio cholerae
MIC = 60 μg/mL) [38] , Neisseria gonorrhoeae (MIC = 75 μg/mL)
30] , Campylobacter coli (MIC = 50 μg/mL) [39] and Arcobacter
ryaerophilu s (MIC = 50 μg/mL) [21] . The inhibitory activity of
esveratrol against Mycobacterium tuberculosis is 100 μg/mL [40] . 
For many bacterial species, resveratrol only displays growth
nhibitory activity at concentrations > 100 μg/mL. Notable Gram-
ositive pathogens with MICs of approximately 10 0–20 0 μg/mL
nclude S. aureus [28,30,33,41] , Enterococcus faecalis [28,33] and
treptococcus pyogenes [30] . Several studies have reported lower
usceptibilities for several Gram-negative pathogens (MIC >
00 μg/mL) compared with Gram-positive pathogens, including E.
oli [33,41] , Klebsiella pneumoniae [33] , Salmonella enterica serovar
yphimurium [33,41] and Pseudomonas aeruginosa [28,33,41] . This
bservation may result from poor penetration of resveratrol across
he outer membrane of some Gram-negative bacteria or be the re-
ult of active extrusion of resveratrol by eﬄux pump systems. 
Since resveratrol inhibits the ATP synthase in different bacte-
ial species, it remains to be explored whether different require-
ents for bacterial energy generation partially account for alter-
ating levels of susceptibility to resveratrol. 
Some remarkable discrepancies exist between reported MICs,
.g. for S. aureus ATCC 25923 the MIC has been reported as
00 μg/mL in one study [33] but as > 10 0 0 μg/mL in another study
42] . One explanation for such variation may be differences in
rowth medium (Mueller–Hinton and Luria–Bertani, respectively), 
owever in general conﬂicting results on resveratrol susceptibility
etween studies warrant additional investigation. 
.3. Inactivation of eﬄux pump systems can increase resveratrol 
usceptibility 
One mechanism that decreases susceptibility to resveratrol is
he presence of functional eﬄux pump systems. In several Gram-
egative bacteria the eﬄux pump AcrAB–TolC actively extrudes
umerous antimicrobials [43] . In E. coli , a tolC mutant displayed
our-fold greater susceptibility to resveratrol compared with the
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Table 1 
Antimicrobial activity of resveratrol against bacteria and fungi. 
Organism Identiﬁer MIC (μg/mL) a Reference 
Gram-positive bacteria 
Bacillus cereus ATCC 11778 50 [33] 
NCTR-466 10 0 0 [42] 
Bacillus megaterium 11561 250 [41] 
Staphylococcus aureus ATCC 25923 100 [33] 
3 clinical isolates 10 0–20 0 [33] 
ATCC 29213 171 [28] 
N315 > 100 [40] 
8325-4 125 [41] 
RN450 150 [66] 
Clinical isolate > 200 [30] 
Clinical isolate 350 [55] 
ATCC 25923 > 10 0 0 [42] 
JE2 256 [25] 
Newman 512 [25] 
COL 128 [25] 
Enterococcus faecalis ATCC 29212 100 [33] 
ATCC 29212 342 [28] 
ATCC 29212 100 [40] 
ATCC 19433 10 0 0 [42] 
ATCC 27274 10 0 0 [42] 
ATCC 29212 128–256 [25] 
Enterococcus faecium D344R 128 [25] 
Mycobacterium tuberculosis H37Rv 100 [40] 
Mycobacterium smegmatis ATCC 70 0 084 (mc 2 155) 64 [34] 
Streptococcus pneumoniae HM145 100 [40] 
Streptococcus pyogenes Clinical isolate > 200 [30] 
Propionibacterium acnes ATCC 25746 180 [45] 
ATCC 29399 186 [45] 
ATCC 33179 196 [45] 
ATCC 6919 > 10 0 0 [42] 
Listeria monocytogenes LMG16779 200 [44] 
LMG16780 200 [44] 
LMG13305 200 [44] 
NCTC7973 128 [25] 
Gram-negative bacteria 
Escherichia coli ATCC 25922 > 400 [33] 
Clinical isolate > 400 [33] 
K-12 500 [41] 
BW25113 400 [66] 
Clinical isolate > 200 [30] 
AG100 > 10 0 0 [42] 
ATCC 47004 250 [42] 
ATCC 35695 > 512 [25] 
Klebsiella pneumoniae ATCC 13883 > 400 [33] 
Clinical isolate > 400 [33] 
ATCC 13883 250 [42] 
ATCC 700721 > 512 [25] 
Salmonella enterica serovar Typhimurium ATCC 13311 > 400 [33] 
ST329 500 [41] 
ATCC 14028 > 10 0 0 [42] 
Pseudomonas aeruginosa ATCC 27853 > 400 [33] 
Clinical isolate > 400 [33] 
ATCC 27853 342 [28] 
PAO1 10 0 0 [41] 
Clinical isolate > 200 [30] 
PAO1 > 10 0 0 [42] 
PAO1 > 10 0 0 [71] 
PAO1 > 512 [25] 
Helicobacter pylori ATCC 43504 25 [35] 
ATCC 700392 50 [36] 
ATCC 700824 50 [36] 
15 clinical isolates 25–100 [36] 
26 clinical isolates 37–1280 (MBC) [37] 
Arcobacter butzleri LMG 10828 100 [21] 
AB36/11 100 [39] 
INSA776 100 [39] 
Arcobacter cryaerophilus LMG 10829 50 [21] 
Haemophilus ducreyi 9 isolates 250–500 (MCC) [46] 
Neisseria gonorrhoeae Clinical isolate 75 [30] 
Neisseria meningitidis ATCC 13090 125 [30] 
Vibrio cholerae MCVO9 60 [38] 
Fusobacterium nucleatum ATCC 10953 100 [52] 
Campylobacter jejuni 225421 100 [39] 
Campylobacter coli 873 50 [39] 
( continued on next page ) 
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Table 1 ( continued ) 
Organism Identiﬁer MIC (μg/mL) a Reference 
Fungi 
Trichophyton mentagrophytes ATCC 18748 25–50 [28] 
Trichophyton tonsurans ATCC 28942 25–50 [28] 
Trichophyton rubrum ATCC 18762 25–50 [28] 
Epidermophyton ﬂoccosum ATCC 52066 25–50 [28] 
Microsporum gypseum ATCC 14683 25–50 [28] 
Candida albicans TIMM 1768 20 [29] 
Clinical isolate > 200 [30] 
ATCC 90028 > 128 [31] 
ATCC 76615 > 128 [31] 
SC5314 > 300 [32] 
Saccharomyces cerevisiae KCTC 7296 10–20 [29] 
Botrytis cinerea SP1 60–140 [11] 
Trichosporon beigelii KCTC 7077 10 [29] 
MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; 
MCC, minimum cidal concentration. 
a Data are the MIC unless otherwise stated. 
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i  ild-type [41] , whilst an acrB mutant was eight-fold more suscep-
ible to resveratrol [42] . Similarly, a P. aeruginosa mutant deﬁcient
n the MexAB–OprM eﬄux pump displayed two-fold greater sus-
eptibility relative to the wild-type [41] . Use of the eﬄux pump
nhibitor phenylalanine-arginine β-naphthylamide (PA βN) reduces
he resveratrol MIC in Arcobacter butzleri and A. cryaerophilus by
6- and 4-fold, respectively [21] . Increased eﬃcacy of resveratrol
n the presence of PA βN has also been observed for E. coli and
roteus mirabilis [42] . 
The observation that inactivation of eﬄux pump function in-
reases the inhibitory activity of resveratrol suggests that the an-
ibacterial eﬃcacy of resveratrol is partially attributed to interac-
ion with cytoplasmic or periplasmic targets in Gram-negative bac-
eria. 
.4. Bacteriostatic or bactericidal effect of resveratrol 
Time–kill curves have been used to determine whether the ef-
ect of resveratrol is bactericidal or bacteriostatic against several
acterial species. At 2–3 ×MIC, resveratrol is bacteriostatic against
acillus subtilis [33] , S. aureus [25,33] , E. faecalis [33] and Liste-
ia monocytogenes [44] . In contrast, resveratrol displays bactericidal
ctivity against Propionibacterium acnes [45] , Haemophilus ducreyi
46] , Campylobacter spp. [39] and Arcobacter spp. [21,39] . Further-
ore, resveratrol displays fungicidal activity against C. albicans
29] . 
. Antivirulence properties 
Virulence is the ability of a pathogen to cause disease in a host,
nd virulence factors are the mechanisms by which the pathogen
auses damage to the host (e.g. by excretion of toxins) as well as
echanisms to establish an infection (e.g. factors for adhesion, in-
asion, colonisation and bioﬁlm production) [47] . Expression of vir-
lence genes is often tightly regulated for timely and co-ordinated
daptation to the environment, e.g. by quorum sensing (QS) or
wo-component systems (TCSs) [47] . The therapeutic applicability
f antivirulence molecules concerns the rationale for disarming the
athogen of abilities to cause harm to the host and relying on the
ost immune system to eradicate the bacteria [48] . The antiviru-
ence properties of resveratrol are highlighted in Table 2 and are
utlined below. 
.1. Antibioﬁlm properties 
Bacteria can live as planktonic cells or in aggregates attached
o surfaces, referred to as bioﬁlms. In bioﬁlms, bacteria producen extracellular material in which the cells are embedded [49] .
he advantage of bioﬁlm formation by bacteria is the establish-
ent of a more stable environment in order to provide pro-
ection against environmental challenges, including phagocytosis
nd antimicrobial agents [50] . Bioﬁlm formation is a clinically
mportant issue as it is associated with chronic and recurrent
nfections [51] . 
Resveratrol has been studied on various bacterial pathogens
or its ability to reduce bioﬁlm formation. For the Gram-negative
naerobic bacterium Fusobacterium nucleatum , which is implicated
n dental plaque, resveratrol inhibits bioﬁlm formation at concen-
rations (4–64-fold below the MIC) that do not affect the growth of
lanktonic cells [52] . Furthermore, resveratrol displays antibioﬁlm
roperties against the Gram-negative pathogens V. cholerae at con-
entrations 2–6-fold below the MIC [38] and E. coli [53] as well
s against the Gram-positive bacterium P. acnes [54] . In E. coli , the
ffect is mediated by reduced expression of genes ( csgA and csgB )
ncoding for curli production, which are important for bioﬁlm for-
ation [53] . For the Gram-positive pathogen S. aureus , resveratrol
nhibits bioﬁlm formation at a concentration 3–4-fold below the
IC, and in combination with vancomycin resveratrol displays a
trong effect in eradicating established bioﬁlms [55] . In contrast,
n two other studies resveratrol did not reduce bioﬁlm formation
n S. aureus [56,57] , indicating that testing conditions and strain
ariation may inﬂuence the impact. 
.2. Antimotility properties 
For several bacterial species, motility is important in the coloni-
ation stage [58] . Motility can occur, for example, via swimming
nd swarming, which require production of functional ﬂagella and
witching that require type IV pili [59] . 
At subinhibitory concentrations of resveratrol, P. mirabilis dis-
lays reduced swarming ability in a dose-dependent manner [60] .
uppression of swarming in the presence of resveratrol is depen-
ent on the TCS protein RsbA, which is a negative regulator of
warming [60] . Resveratrol reduces swimming and swarming in E.
oli through downregulation of several motility and ﬂagella genes
53] . Reduced swarming ability has also been reported for Vibrio
ulniﬁcus [61] . 
.3. Toxin interference 
Bacterial pathogens secrete a multitude of structurally and
unctionally different toxins and they are often highly important
n the development of disease [47] . Interestingly, a few reports
720 M. Vestergaard and H. Ingmer / International Journal of Antimicrobial Agents 53 (2019) 716–723 
Table 2 
Antivirulence properties of resveratrol. 
Virulence factor Effect and organism Concentration (μg/mL) Reference 
Bioﬁlm Reduction in bioﬁlm production by Fusobacterium nucleatum 1.5625–25 [52] 
Reduction in bioﬁlm production by Escherichia coli 50–100 [53] 
Reduction in bioﬁlm production by Propionibacterium acnes [54] 
Reduction in bioﬁlm production by Vibrio cholerae 10–30 [38] 
Reduction in bioﬁlm production by Staphylococcus aureus 100–150 [55] 
No reduction in bioﬁlm formation by S. aureus 20–100 [57] 
No reduction in bioﬁlm formation by S. aureus 100 [56] 
Reduction in bioﬁlm production by Burkholderia spp. 25 μM [65] 
Reduction in bioﬁlm production by Arcobacter butzleri and Campylobacter spp. 12.5–50 [39] 
Reduction in bioﬁlm production by Listeria monocytogenes 50–100 [44] 
Motility Reduction in swarming by E. coli 20 [53] 
Reduction in swarming by Proteus mirabilis 15–60 [60] 
Reduction in swarming by Vibrio vulniﬁcus 30 μM [61] 
Quorum sensing (QS) Reduction in QS by Yersinia enterocolitica 10–20 [64] 
Reduction in QS by Burkholderia spp. 25 μM [65] 
Toxins Reduced haemolysis by P. mirabilis 30–60 [60] 
Reduced haemolysis by S. aureus 20 [57] 
Reduced haemolysis by S. aureus 10–100 [56] 
Reduced toxin expression by V. vulniﬁcus 10–30 μM [61] 
Suppressed toxin activity by V. cholerae 30 0–40 0 μM [62] 
Adhesion Reduced adhesion to host cells by V. vulniﬁcus 10–30 μM [61] 
Colonisation Decreased urease activity by Helicobacter pylori 6.25–400 [36] 
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p  indicate that resveratrol in some cases interferes with toxin ex-
pression. In V. vulniﬁcus , RtxA1 is a multifunctional cytotoxic
toxin important for lethality in mice, and resveratrol treatment
reduces rtxA1 expression [61] . In V. cholerae , resveratrol in-
hibits cholera toxin (CT) endocytosis into host cells and directly
binds CT and hence may potentially inhibit CT-induced diar-
rhoea [62] . Resveratrol also greatly inhibits haemolysis of human
blood cells by S. aureus , but the mechanism of inhibition remains
unknown [56,57] . 
5.4. Interference with quorum sensing (QS) 
QS systems enable bacteria to respond to cell density and,
through cell–cell communication, to regulate gene expression. In
bacterial pathogens, QS often controls virulence gene expression
allowing a co-ordinated attack that may overwhelm host defences
[63] . QS involves the production and release of signal molecules,
called autoinducers, that increase as a function of cell density. A
threshold limit of the autoinducer is detected by the bacteria, lead-
ing to alterations in gene expression [63] . In Yersinia enterocolitica
and Erwinia carotovora , resveratrol inhibits synthesis of the autoin-
ducers N -acyl-homoserine lactones at a concentration that does
not affect growth parameters [64] . Resveratrol also interferes with
QS systems in E. coli and Chromobacterium violaceum through an
uncharacterised mechanism [65] . 
Taken together, resveratrol affects multiple virulence traits at
concentrations up to 64-fold below growth-inhibitory concentra-
tions. Whether resveratrol may have any applications as an an-
tivirulence compound needs to be assessed in suitable animal
models. 
6. Resveratrol in combination with conventional antimicrobials 
In addition to working as an antimicrobial compound by
itself, resveratrol has also been investigated for potential ef-
fects in combination with conventional antibiotics. In E. coli ,
resveratrol (at 0.5 ×MIC) antagonises the bactericidal activity of
ciproﬂoxacin, kanamycin, oxolinic acid and moxiﬂoxacin, whereas
oxacillin lethality is unaffected [66] . For S. aureus , resveratrol
antagonises the lethal activity of daptomycin, moxiﬂoxacin and
oxacillin [66] and levoﬂoxacin [67] . The mechanism of antagonisms suggested to involve a reduction in reactive oxygen species (ROS)
y resveratrol [66] , which has antioxidant properties and thus pro-
ects macromolecules against damage by ROS [68] . Generation of
OS has been implicated as contributing to the lethality of bac-
ericidal antibiotics [69] and, by scavenging ROS, resveratrol may
uppress the bacterial killing with the mentioned antibiotics [66] . 
In contrast, resveratrol (at 0.5 ×MIC) potentiates the eﬃcacy
f aminoglycosides approximately 16-fold against S. aureus and
o a lesser extent against other Gram-positive pathogens such as
taphylococcus epidermidis, Enterococcus faecium and E. faecalis [25] .
he mechanism of potentiation has been hypothesised to occur via
nhibition of ATP synthase [25] , as inactivation of genes encoding
TP synthase in S. aureus also sensitises this pathogen to aminogly-
osides [70] . Furthermore, resveratrol enhances aminoglycoside ac-
ivity against bioﬁlms produced by P. aeruginosa , however the com-
inations of resveratrol and four different aminoglycosides did not
isplay synergy on planktonic cells [71] . 
Taken together, resveratrol interferes with the inhibitory activ-
ty of different classes of antibiotics. Whether these effects are also
vident in animal models remain to be explored. 
. In vivo antimicrobial activity of resveratrol 
Several studies in humans have demonstrated that resvera-
rol displays high absorption yet low bioavailability of unchanged
esveratrol following oral administration [72,73] . Resveratrol is
eadily metabolised following oral administration, with sulfate–
nd glucuronide–resveratrol conjugates reaching 3–8-fold higher
lasma concentrations than free resveratrol [73] . Following oral ad-
inistration of 5 g of trans -resveratrol as a single dose, the peak
lasma level of resveratrol was 539 ng/mL at 1.5 h after adminis-
ration and the mean plasma concentration was approximately 52
g/mL at 24 h after administration [73] . Similarly, oral administra-
ion of 1 g of resveratrol resulted in an average 73 ng/mL of resver-
trol in plasma after 1 h [74] . The low bioavailability of orally ad-
inistered resveratrol limits this route of administration for poten-
ial systemic use of resveratrol for the treatment of bacterial infec-
ions, considering the inhibitory concentrations needed. Given that
here is rapid turnover of resveratrol in humans and that higher
lasma concentrations of resveratrol conjugates are observed com-
ared with the non-modiﬁed compound, it could be interesting
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 o investigate the antimicrobial properties of such conjugates. In-
ravenous (i.v.) administration of resveratrol has also been investi-
ated in humans, however the administered dose was low (0.2 mg)
nd resveratrol was still quickly metabolised [72] , indicating that
.v. administration of resveratrol may also have limited, if any, an-
imicrobial applications for systemic infections. Finally, topical ad-
inistration of resveratrol may still potentially enable the use of
oncentrations with a beneﬁcial effect against different infectious
iseases. 
A few studies have investigated the therapeutic application of
esveratrol against infectious diseases in animal models or human
rials. The bacterium P. acnes is a contributing factor in the patho-
enesis of acne vulgaris, one of the most common skin diseases
75] . In a human study, acne vulgaris patients treated with resver-
trol (at a concentration of 1 mg/g of ﬁnal preparation) experi-
nced a signiﬁcant reduction in facial acne lesions compared with
reatment with the vehicle alone. Whether the therapeutic effect
f resveratrol on acne vulgaris is a result of antimicrobial or anti-
nﬂammatory properties was not elucidated in the study [76] . In
ontrast, in a study of experimental periodontitis in rats, continu-
us use of resveratrol did not promote any beneﬁcial effect in re-
ucing important oral periodontopathic bacteria [77] . Furthermore,
opical application of resveratrol reduces lesion formation on the
kin of mice by herpes simplex virus [78] and reduces replication
f herpes simplex virus in the vagina of mice [79] . 
More studies are required to elucidate the potential of topical
dministration of resveratrol for the control of bacterial and fungal
kin diseases, potentially in combination with conventional antimi-
robials. 
. Conclusion 
Resveratrol has gained signiﬁcant scientiﬁc and public inter-
st owing to acclaimed health-beneﬁcial effects [1] . Substantial
ork conducted in vitro and in various animal models has doc-
mented potential beneﬁts to human health following administra-
ion of resveratrol, however such beneﬁts still remain to be doc-
mented in human clinical phase 3 trials [80] . Although clinical
vidence for the acclaimed health beneﬁts is largely lacking [1,80] ,
esveratrol has still gained signiﬁcant market traction as a dietary
upplement [81] . In a recent survey, 18% of respondents in the USA
ad used resveratrol supplements, whereas only 3% had used them
n Denmark [81] . 
In addition to the potential effects of resveratrol on various dis-
ases, e.g. cancer, the compound also displays antimicrobial prop-
rties against bacterial, fungal and viral pathogens. As detailed in
his review, resveratrol can inhibit bacterial and fungal growth, al-
er the expression of virulence factors, reduce bioﬁlm formation,
educe motility and affect the susceptibility of bacteria to various
lasses of conventional antibiotics ( Tables 1 and 2 ). However, the
ntimicrobial properties of resveratrol displayed in vitro are all at
igher concentrations than have currently been achieved in hu-
an plasma following oral administration [72] . The low bioavail-
bility of orally administered resveratrol limits this route of ad-
inistration for systemic use of resveratrol for the treatment of
acterial and fungal infections [73] . However, it is currently not
nown whether metabolised resveratrol conjugates retain antimi-
robial activity. If resveratrol conjugates retain antimicrobial activ-
ty, the plasma concentrations of effective resveratrol and deriva-
ives may potentially be higher than currently expected. 
An avenue for exploration of resveratrol as an antimicrobial
gent is via topical administration, where higher concentrations
f resveratrol are achievable. One human study demonstrated a
ositive effect on lesion reduction in acne vulgaris, however it is
ot known whether this effect is due to antibacterial properties
gainst P. acnes [76] . The ﬁeld of in vivo antimicrobial eﬃcacy ofesveratrol remains largely unexplored, and future studies are war-
anted to elucidate antimicrobial eﬃcacy following topical admin-
stration to treat various skin infections. Furthermore, resveratrol
nteracts with the eﬃcacy of certain classes of conventional antibi-
tics and this may be needed to be taken into consideration during
ntibiotic regimen design [25,66] . Resveratrol potentiates the eﬃ-
acy of aminoglycosides against several Gram-positive pathogens,
nd combinations should be tested in viv o for enhanced treat-
ent eﬃcacy [25] . Therefore, it will be interesting to investigate
n animal models whether resveratrol can have any applicability
s a potentiator for aminoglycosides. In contrast, the implication
f resveratrol consumption as a dietary supplement could also po-
entially reduce the eﬃcacy of certain antibiotic classes such as
uoroquinolones [66,67] , which requires further investigations in
nimal models. As with so many other antimicrobial compounds,
roblems with resistance may arise and, as an example, enzymatic
nactivation of resveratrol has been demonstrated [82] . Investiga-
ions in suitable animal models are greatly needed to assess the
linical potential of resveratrol as monotherapy or in combination
ith conventional antibiotics. 
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